Organic Active Ingredients TRIZ Cases

N-sulfated hexasaccharide mimetics with glucuronic acid units improve heparanase inhibition while avoiding full heparin complexity.

Combining TTFields with IGF1R, JNK, RPS6, or ERK inhibitors helps overcome cancer cell resistance and prolong treatment efficacy.

Small molecules bind the BCL6 BTB domain to block corepressor recruitment, suppress malignant proliferation, and support cancer treatment.

Deuterium substitution in diarylpyrazole BRAF inhibitors slows metabolism, improving oral exposure, clearance, and side-effect control.

Continuous Coenzyme Q10 infusion at adjusted rates helps treat brain cancer while limiting coagulopathy, myelosuppression, and other severe side effects.

Controlled surface tension, viscosity, and tip-seal packaging keep preservative-free eye drops stable while improving dosing consistency.

A selective NF2 compound blocks TβR1-mediated RKIP reduction to suppress schwannoma stemness without disrupting normal TGF-β signaling.

Selective imidazole derivatives improve α2 agonist sedation and analgesia while limiting hypotension, bradycardia, and vasoconstriction.

TMPRSS6-targeting nucleic acids paired with iron chelators lower iron levels while balancing silencing potency, specificity, and toxicity.

A 2-azaspiro[3.3]heptane scaffold improves M4 selectivity to treat neurological disorders while limiting cognitive, cardiac, and GI side effects.

Chemically synthesized imidazopyrimidines modulate IL-17A to enable oral treatment of inflammatory disorders with lower cost and broader access.

Combined organ and donor hematopoietic cell transplantation establishes stable mixed chimerism, enabling drug withdrawal while limiting rejection and GVHD.

Symmetrical core-shell microparticles improve flight stability, reduce stickiness, and raise fine particle fraction for more uniform lung delivery.

Defined sodium salt crystal forms improve stability, solubility, and low hygroscopicity for HIV integrase inhibitor formulation.

Combined alder and elm extracts suppress inflammatory cytokines and protect muscle cells to address sarcopenia and periodontal disease together.

A viscosity-tuned ocular laquinimod gel improves posterior eye delivery through the corneal barrier while limiting systemic side effects.

Bicyclic scaffolds target SH2 and catalytic regions to create selective small-molecule SHP2 inhibitors for disease treatment.

Higher β1-3 Gal-Gal oligosaccharide content helps selectively stimulate beneficial gut bacteria and support a balanced intestinal environment.

Blocking CD97-GSDME interaction makes double-positive tumor cells more vulnerable to NK killing and pyroptosis, improving chemo-immunotherapy response.

By inhibiting sEH, piperidine urea compounds extend EET activity to reduce neuroinflammation, limit synuclein aggregation, and support neuronal survival.

Combining BCAAs with L-Alanine improves amino acid absorption and muscle protein synthesis to help maintain muscle mass and function.

These substituted pyridoindoles stimulate chondrogenesis, collagen II, and aggrecan synthesis to help restore damaged cartilage in osteoarthritis.

Adding H2S measurement to breath testing improves SIBO diagnosis and helps guide targeted treatment for diarrhea, fatigue, and abdominal pain.

These piperidine urea compounds boost myocardial contractility in DCM by enhancing myosin phosphate release without prolonging systole.

Controlled crystallization of an oral GLP-1 agonist improves chemical stability, filtration, and powder flow for production and storage.

Controlled fleece basis weight, thickness, and porosity tailor oral pouch flavor and active release while preserving pouch strength.

Using the FGFR4 inhibitor free base with selected excipients improves powder flow, dissolution, and content uniformity for industrial production.

A solid oral CaSR agonist composition lowers PTH in SHPT without dose titration, helping reduce GI side effects and improve adherence.

miRNA binding sites in the Poly(A) tail guide tissue-specific mRNA expression, reducing off-target accumulation and side effects.

Magnesium chloride boosts naloxone absorption after injection, cutting lag to therapeutic levels and enabling faster overdose treatment.

A buffered bosentan eye drop uses castor-oil solubilizers to reach the retina and reduce glial activation and apoptosis without systemic side effects.

Targeting FRS2β-expressing cells with CXCR7 inhibitors disrupts the CSC niche to limit tumor growth and herceptin-resistant recurrence.

Controlled pH adjustment in water-isopropanol produces stable pemetrexed diacid crystal forms with high yield, easier drying, and scale-up.

A dual ANO1-EGFR inhibitor composition suppresses brain tumor growth and migration while helping overcome resistance and improve EGFR therapy.

Blocking IL-6 signaling with receptor or IL-6 antibodies helps control refractory severe asthma, reducing exacerbations and improving respiratory function.

Modified antisense oligonucleotides use phosphorothioate and 2'-O-methoxyethyl chemistry to lower PKK mRNA and protein with better stability.

Small-droplet lipid eye emulsions use mucoadhesive galactomannan to prolong hydration and reduce blurring from oil globules.

Internalizing anti-HER3 antibodies block HER3 signaling and deliver cytotoxic or immune payloads to tumors with EGFR or HER2-driven resistance.

A carbamate-linked prodrug conjugate enables non-enzymatic cleavage under physiological conditions for more predictable release of sensitive drugs.

A fixed-dose bictegravir and lenacapavir tablet simplifies HIV dosing while maintaining pharmacokinetics and therapeutic efficacy.

Crosslinked and uncrosslinked hyaluronic acid gel occludes the canaliculus to retain tears, easing dry eye with minimal irritation.

A c-Met targeting peptide linked to a taxane improves water solubility and tumor selectivity while reducing systemic toxicity.

Periodic recombinant LAL dosing restores enzyme activity, growth, and liver function while reducing treatment burden in LAL deficiency.

APAC competes with heparin to block and dissociate PF4 complexes, reducing HIT-related thrombosis risk with lower bleeding risk.

Low-molecular-weight substituted imidazoles inhibit TGF-β signaling while improving therapeutic index, formulation, and tissue distribution.

Modified citrin mRNA in lipid nanoparticles restores hepatic Citrin activity and lowers ammonia and triglycerides in CTLN2.

Crystalline, amorphous, and salt forms of this myeloma compound improve stability and bioavailability while helping reduce toxicity and side effects.

Pyrimidine derivatives are tuned to inhibit EGFR mutants such as T790M while sparing wild-type EGFR, helping reduce adverse effects.

A lyophilized gelatin-mannitol oral mucosal CBD dose improves bioavailability, dosing accuracy, and rapid pain relief.

Specific PLK1 inhibitor crystal salts improve stability and oral bioavailability, helping widen safety margins for anti-tumor therapy.

A diazanylidenesulfonyl compound activates PKR to raise ATP and hemoglobin, offering oral anemia treatment beyond transfusion or transplant.

Ethylene treatment in darkness raises isoflavone derivatives in soybean leaves while avoiding energy-intensive LED lighting and ethephon use.

Selective oxadiazolyl dihydropyrano[2,3-b]pyridines inhibit Smad3 activation to treat kidney fibrosis while addressing solubility and potency limits.

Domain-targeted NIC7 and NIC7w improve NLRP3 inhibition specificity and potency while reducing IL-1β and caspase 1 activity.

Novel spiro pyridopyrimidinone compounds improve kinase selectivity and broad inhibition while maintaining low cytotoxicity for cancer therapy.

Using jellyfish collagen in wound dressings improves angiogenesis, lowers immunogenicity, and reduces virus transmission risk.

Adding amino or heterocyclic groups to a 2'-carbamoyl ethyl nucleoside improves oligonucleotide nuclease resistance and drug stability.

A topical filter blocks UVA while transmitting therapeutic UVB at 295-320 nm to treat inflammatory skin diseases with fewer side effects.

A topical oxymetazoline cream with emollients treats rosacea erythema while improving cosmetic acceptability and limiting skin irritation.

TLE1 expression is used to predict brincidofovir sensitivity, helping match malignant tumor patients to treatment with more reliable efficacy.

Drug-loaded microneedle tips localize chemotherapeutic agents to cut waste, improve dosage control, and enable efficient co-delivery.

Optimized solvents, temperature, and inert processing improve clazosentan disodium salt purity, filterability, handling, and yield.

A PLGA-DMSO risperidone depot reaches therapeutic levels within 24 hours and sustains 28-day schizophrenia treatment without loading doses.

Cyclic stretching on auxetic cell substrates boosts exosome yield and builds anti-HLA-G targeting for cancer drug delivery.

Biocompatible particle complexes embedded in a biodegradable gel protect biological species from degradation and reduce cold-chain dependence.

Aerosolized CFTR mRNA formulations use lipid nanoparticles and optimized mRNA design to enable lung expression while avoiding viral-vector immune barriers.

Periodic IV anti-alpha-synuclein antibody dosing targets protein deposits and helps improve motor and cognitive deficits in Lewy body diseases.

Targeting FAP adipogenesis with AnxA2, MMP, or TLR inhibitors helps limit fibrosis and muscle degeneration in muscular dystrophy.

A layered fixed-dose HIV tablet combines three antivirals to maintain pharmacokinetics and stability while reducing pill burden.

Crystalline alkaloid salt particles with sugar alcohol reduce moisture uptake and agglomeration, extending inhalable powder shelf life.

A besylate crystal form of mesembrine improves water solubility and stability, enabling higher-concentration pharmaceutical preparation.

Aqueous-base synthesis and crystallization enable rabeximod production at industrial scale with high purity and GMP-ready process control.

6-thio-dG exploits telomerase to damage telomeres, trigger apoptosis, and suppress therapy-resistant pediatric brain tumors.

Selective pyrazolopyrimidine ATR inhibitors improve cancer cell killing while limiting normal-cell toxicity and boosting chemo or radiotherapy response.

Structural changes to amide EZH2 inhibitors improve target selectivity and in vivo efficacy for treating EZH2-mediated tumors.

A derivatized chitosan polyglucosamine helps restore gut integrity after radiation, trauma, or shock to reduce sepsis severity and mortality.

Combining alternating electric fields with PI3K, AKT, mTOR, or GSK3β inhibitors helps overcome cancer cell resistance and increase apoptosis.

A leucine-linked tRNA modulates HIV ribosome frameshifting to disrupt the gag:gag-pol ratio, reducing propagation without altering cellular gene expression.

Cbl inhibitors boost immune cell expansion and activation in one step, improving cell therapy durability and solid tumor response.

Radical-quenching substituted pyrimidines suppress ROS and lipid peroxidation to preserve mitochondrial function, membrane potential, and ATP.

Immunophilin-binding compounds act as mediators to improve CNS delivery of mTOR inhibitors while reducing systemic toxicity and immunosuppression.

Adding 2′-FL, 3-FL, and related HMOs to formula shifts gut fermentation, lowers pH, and reduces branched chain fatty acids.

A bone-targeting conjugate combines bisphosphonate action with Ron kinase inhibition to curb osteolysis, metastatic outgrowth, and cancer progression.

Heterocyclic Formula I compounds stimulate cardiomyocyte proliferation and regeneration to limit irreversible heart damage after infarction or failure.

Novel KHK inhibitor structures use heterocyclic and cycloalkyl groups to balance tissue distribution while reducing toxicity and drug interactions.

Controlled oral minoxidil release sustains serum levels over time, reducing fluctuation, adverse effects, and frequent dosing in hair loss treatment.

An oleogel mucoadhesive gel resists fluid clearance to extend mucosal residence time and improve systemic delivery without first-pass metabolism.

Defined CCR4 inhibitor structures reduce broad screening effort and speed discovery of compounds for CCR4-mediated inflammatory diseases.

Controlled oral minoxidil release maintains steadier serum levels to support hair regrowth while reducing fluctuation-driven adverse effects.

Crystalline forms of a PRC2 inhibitor target EED to improve inhibition efficacy, limit EZH2 resistance pathways, and maintain humidity stability.

Microbial strains and metabolites modulate metabolic pathways to improve insulin-associated disease treatment and enable subject-specific therapy.

Novel aldose reductase inhibitors are tuned to cross the blood-brain barrier while preserving neuroprotective activity in ischemic stroke.

Novel Formula I and II compounds inhibit RIPK2 and disrupt RIPK2/XIAP signaling to treat inflammatory diseases with refractory patient response.

A selective reductive route forms 2-hydroxyethyl aminocaproate compounds for ionizable lipids that improve mRNA delivery and organ targeting.

A fused ring compound uses targeted substituent changes to inhibit STAT6 and support treatment of allergic and inflammatory diseases.

Selective mPGES-1 inhibition with pyrimidine derivatives suppresses PGE2 while avoiding gastric injury and supporting rapid oral absorption.

Real-time RFID UIDs and package genealogy improve cannabis traceability, curb diversion, and lower regulatory overhead.

Fluorinated VMAT2 inhibitor compounds extend half-life and improve brain exposure to treat tardive dyskinesia with fewer adverse reactions.

Host-targeted thiazole and isoquinoline compounds block RNA and DNA virus replication while reducing resistance from viral mutation.

Novel CFTR corrector and potentiator compounds address F508del misfolding and poor anion transport to reduce mucus buildup in cystic fibrosis.